|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2010-5-10
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Antagonism of corticotropin-releasing factor (CRF) receptors has been hypothesized as a potential target for the development of novel anxiolytics. This study was designed to determine the safety and efficacy of pexacerfont, a selective CRF-1 receptor antagonist, in the treatment of generalized anxiety disorder (GAD).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1520-6394
|
|
pubmed:author |
pubmed-author:CoricVladimirV,
pubmed-author:D'SouzaBernadette BBB,
pubmed-author:DelmonteTerryeT,
pubmed-author:DockensRandy CRC,
pubmed-author:EmisonEileenE,
pubmed-author:FeldmanHoward HHH,
pubmed-author:GentileKimberly AKA,
pubmed-author:GoddardAndrew WAW,
pubmed-author:GrebbJack AJA,
pubmed-author:HuangShu-PangSP,
pubmed-author:OrenDan ADA,
pubmed-author:PultzJosephJ,
pubmed-author:ShekharAnanthaA,
pubmed-author:StockElyse GEG,
pubmed-author:WuXiaolingX,
pubmed-author:ZimbroffDaniel LDL
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
27
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
417-25
|
|
pubmed:meshHeading |
pubmed-meshheading:20455246-Adolescent,
pubmed-meshheading:20455246-Adult,
pubmed-meshheading:20455246-Aged,
pubmed-meshheading:20455246-Anti-Anxiety Agents,
pubmed-meshheading:20455246-Anxiety Disorders,
pubmed-meshheading:20455246-Citalopram,
pubmed-meshheading:20455246-Diagnostic and Statistical Manual of Mental Disorders,
pubmed-meshheading:20455246-Double-Blind Method,
pubmed-meshheading:20455246-Female,
pubmed-meshheading:20455246-Humans,
pubmed-meshheading:20455246-Male,
pubmed-meshheading:20455246-Middle Aged,
pubmed-meshheading:20455246-Pharmacogenetics,
pubmed-meshheading:20455246-Phenotype,
pubmed-meshheading:20455246-Polymorphism, Single Nucleotide,
pubmed-meshheading:20455246-Psychometrics,
pubmed-meshheading:20455246-Pyrazoles,
pubmed-meshheading:20455246-Receptors, Corticotropin-Releasing Hormone,
pubmed-meshheading:20455246-Severity of Illness Index,
pubmed-meshheading:20455246-Triazines,
pubmed-meshheading:20455246-Young Adult
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder.
|
|
pubmed:affiliation |
Bristol-Myers Squibb Company, Neuroscience Global Clinical Research, Wallingford, Connecticut 06492, USA. vlad.coric@bms.com
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
